Kamphuis Lieke S J, van Laar Jan A M, Kuijpers Robert W A M, Missotten Tom, Thio H Bing, van Hagen P Martin
Erasmus Medisch Centrum, Afd. Interne Geneeskunde, Rotterdam, the Netherlands.
Ned Tijdschr Geneeskd. 2010;154(47):A1685.
Sarcoidosis is a granulomatous disease of unknown etiology. Standard treatment with immune suppressants such as glucocorticoids is started when vital organ function is threatened. Biotechnology has resulted in new treatments ('biologicals'), in particular monoclonal antibodies, that may be effective in the treatment of sarcoidosis. In patients with sarcoidosis, only the use of monoclonal antibodies that block tumour necrosis factor (TNF) has been studied scientifically, other biologicals hardly at all. TNF-blockers are used at present in patients with therapy refractory sarcoidosis.
结节病是一种病因不明的肉芽肿性疾病。当重要器官功能受到威胁时，开始使用糖皮质激素等免疫抑制剂进行标准治疗。生物技术带来了新的治疗方法（“生物制剂”），特别是单克隆抗体，它们可能对结节病的治疗有效。在结节病患者中，仅对阻断肿瘤坏死因子（TNF）的单克隆抗体的使用进行了科学研究，其他生物制剂几乎未作研究。目前，TNF阻滞剂用于治疗难治性结节病患者。
